Agios Pharmaceuticals, Inc. (AGIO) Dividend History

Agios Pharmaceuticals, Inc. is a biotechnology company focused on developing targeted therapies for cancer and rare genetic metabolic disorders. Founded in 2007 and based in Cambridge, Massachusetts, Agios specializes in precision medicine strategies, aiming to improve outcomes for patients through innovative small-molecule drugs. The company's portfolio includes treatments targeting metabolic pathways fundamental to cancer cell growth and survival.

88 Sidney Street, Cambridge, MA, 02139
Phone: 617-649-8600
Website: https://www.agios.com

Dividend History

Agios Pharmaceuticals, Inc. currently does not pay dividends

Company News

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

Agios Pharmaceuticals, a leader in cellular metabolism and pyruvate kinase (PK) activation, announced that it will be presenting at the Goldman Sachs 46th Annual Global Healthcare Conference and the 2025 RBC Capital Markets Global Healthcare Conference. The company will highlight its PK activation portfolio and new data in rare blood disorders.

GlobeNewswire Inc.
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

Agios Pharmaceuticals will present new data on its pyruvate kinase activators, mitapivat and tebapivat, at the 30th European Hematology Association Congress. The data covers the use of these therapies in treating rare blood disorders such as sickle cell disease, thalassemia, and pyruvate kinase deficiency.

GlobeNewswire Inc.
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

Agios Pharmaceuticals, a leader in cellular metabolism and PK activation, announced upcoming presentations at healthcare conferences and reported its Q1 2025 financial results.

GlobeNewswire Inc.
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

Agios Pharmaceuticals, a leader in cellular metabolism and PK activation, announced its financial results for the first quarter of 2025. The company is advancing a robust clinical pipeline of investigational medicines for rare diseases.

GlobeNewswire Inc.
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Agios Pharmaceuticals, a leader in cellular metabolism and pyruvate kinase (PK) activation, announced it will host a conference call to report its Q1 2025 financial results and business highlights. The company is advancing a robust clinical pipeline of investigational medicines for rare diseases.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 11:45:24 UTC